Non Hodgkin Lymphoma News and Research

RSS

Study reveals HCT as effective treatment for NHL patients regardless of age

Results from a retrospective study of 1,629 patients with non-Hodgkin lymphoma showed that survival at 4 years following allogeneic hematopoietic cell transplantation for patients age 65 years and older is comparable to patients age 55 to 64 years.

21 Feb 2018

Caris Life Sciences reveals identification of new mechanism of action to treat NHL

Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced a data presentation, at the 59th American Society of Hematology Annual Meeting & Exposition in Atlanta, demonstrating the identification of a new mechanism of action to treat non-Hodgkin lymphoma (NHL).

13 Dec 2017

Researchers question exclusion of people with prior cancer history from clinical trials

A quarter of newly diagnosed cancer patients 65 or older are survivors who had a prior cancer – often preventing them from participating in clinical trials, researchers from UT Southwestern's Simmons Cancer Center have found.

22 Nov 2017

California cracks down on weed killer as lawsuits abound

Jack McCall was a fixture at the local farmers market, where he sold avocados and other fruits he grew on his 20-acre ranch in Cambria, on California's Central Coast.

8 Nov 2017

New category of immunotherapy appears safe to use in patients with both cancer and HIV

A new category of immunotherapies called checkpoint inhibitors that has been highly effective against many different cancers appears safe to use in patients with both advanced malignancies and HIV, a population excluded from earlier trials of such therapies, according to an early-phase trial.

7 Nov 2017

FDA grants accelerated approval to new treatment for mantle cell lymphoma

The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.

1 Nov 2017

VICC selected to administer FDA-approved CAR T therapy for treatment of lymphoma patients

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma.

25 Oct 2017

Dana-Farber, Brigham and Women's Cancer Center certified to offer new CAR T-cell therapy

Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women's Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administration today.

20 Oct 2017

New CAR-T cell therapy offers effective option for certain blood cancer patients

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers.

19 Oct 2017

Novel gene expression signature assay could help enhance lymphoma management

Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment of DLBCL may depend on identifying its molecular subtype.

17 Oct 2017

Study provides detailed characterization of neurotoxicity arising from CD19 CAR T-cell therapy

New potential biomarkers and a novel algorithm could help identify patients at increased risk of suffering from severe neurotoxicity after receiving CD19 CAR T-cell therapy. The study extensively characterized common and occasionally fatal side effects of this immunotherapy.

12 Oct 2017

FDA grants accelerated approval to new drug for treating relapsed follicular lymphoma

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies.

14 Sep 2017

Female cancer survivors have higher risks of poor pregnancy outcomes, study finds

An International Journal of Cancer study found that female survivors of certain types of cancer have higher risks of poor outcomes in pregnancies conceived after diagnosis than women without cancer.

12 Sep 2017

Study identifies late effects that may interfere with work status of young adult cancer survivors

Factors that limit the work ability of young adult cancer survivors are reported today at the ESMO 2017 Congress in Madrid.

11 Sep 2017

FDA approves fixed dose combination chemotherapy for subtypes of AML that have poor survival outcomes

The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.

3 Aug 2017

Infographic displays facts and information about stem cells, cord blood

Over 40,000 people have successfully stored stem cells with Smart Cells, however the industry is still relatively unknown and often subject to misinformation. In a bid to increase awareness and understanding of stem cell collection at birth, Smart Cells have created an informative infographic.

17 Jul 2017

Cord-blood-derived natural killer cells can be modified to destroy B-cell cancers

Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia.

13 Jul 2017

Differential RNA splicing may play role in prostate cancer disparities in African-American men

A form of genetic variation, called differential RNA splicing, may have a role in tumor aggressiveness and drug resistance in African American men with prostate cancer.

30 Jun 2017

FDA authorizes marketing of test to aid in diagnoses of serious cancers

The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).

29 Jun 2017

Study finds steady decline in severe health problems for childhood cancer survivors

Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems occurring five or more years after diagnosis has declined over time.

5 Jun 2017